Who Paid My Doc
A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the S
Research payments
$850,780
Through program year 2025, $850,780 in research payments was reported against A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the S, across 235 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $60,465 | 28 |
| 2024 | Research | $195,128 | 47 |
| 2023 | Research | $405,533 | 116 |
| 2022 | Research | $189,655 | 44 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Malin Hultcrantz Basking Ridge, NJ Named on 50 payments
- Jesus Berdeja Nashville, TN Named on 33 payments
- Hakan Kaya Spokane Valley, WA Named on 22 payments
- Bertrand Anz Chattanooga, TN Named on 17 payments
- Saleha Sajid Kingwood, TX Named on 15 payments
- Shachar Peles Palm Beach Gardens, FL Named on 14 payments
- Gustavo Fonseca New Port Richey, FL Named on 11 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.